Bone Index

Bone Index is a commercial-stage diagnostics company focused on revolutionizing osteoporosis screening with its FDA-cleared and CE-marked Bindex® device. The technology offers a fast, accurate, and radiation-free alternative to traditional DXA scans, having conducted over 4 million scans globally with a reported 90% accuracy compared to DXA. Backed by over a decade of proprietary research and peer-reviewed studies, the company targets primary care, orthopedic clinics, and mobile screening services to enable earlier detection and management of osteoporosis. Its business model is based on the sale of its diagnostic devices and associated consumables.

Portable, radiation-free ultrasound device that measures cortical bone thickness at the calcaneus to assess bone density and osteoporosis risk via proprietary algorithms.

Bone Index competes primarily with central DXA scanners (GE, Hologic) and other point-of-care technologies like quantitative ultrasound (QUS) devices. Its key differentiation is its specific focus on cortical bone measurement, portability, and strong clinical validation. Competition also comes from other diagnostic modalities under development and from the general inertia of the existing standard of care.